Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.11
+0.21 (3.04%)
At close: May 22, 2025, 4:00 PM
7.12
+0.01 (0.14%)
After-hours: May 22, 2025, 5:07 PM EDT
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Atara Biotherapeutics stock ranges from a low of $11 to a high of $25. The average analyst price target of $17.75 forecasts a 149.65% increase in the stock price over the next year.
Price Target: $17.75 (+149.65%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +139.10% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +139.10% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +251.62% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
35.02M
from 128.94M
Decreased by -72.84%
Revenue Next Year
32.30M
from 35.02M
Decreased by -7.77%
EPS This Year
-5.12
from -11.41
EPS Next Year
-4.13
from -5.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.7M | 63.0M | 63.0M | ||
| Avg | 35.0M | 32.3M | 24.5M | ||
| Low | n/a | 2.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -23.5% | 79.9% | 95.0% | ||
| Avg | -72.8% | -7.8% | -24.2% | ||
| Low | - | -91.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.62 | -0.37 | 1.47 | ||
| Avg | -5.12 | -4.13 | -3.14 | ||
| Low | -7.95 | -7.65 | -6.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.